Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

BACKGROUND: Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, which share similar high efficacy rates. Consequently, more emphasis is being placed upon the individual’s experience of treatment and impact on quality of life. The first long-acting...

Descripción completa

Detalles Bibliográficos
Autores principales: Chounta, Vasiliki, Overton, Edgar T., Mills, Anthony, Swindells, Susan, Benn, Paul D., Vanveggel, Simon, van Solingen-Ristea, Rodica, Wang, Yuanyuan, Hudson, Krischan J., Shaefer, Mark S., Margolis, David A., Smith, Kimberly Y., Spreen, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563641/
https://www.ncbi.nlm.nih.gov/pubmed/34056699
http://dx.doi.org/10.1007/s40271-021-00524-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563641/
https://www.ncbi.nlm.nih.gov/pubmed/34056699
http://dx.doi.org/10.1007/s40271-021-00524-0

Ejemplares similares